Call Us:  +1.302.777.7774

CECON logo

Log in

Login to your account

Username *
Password *
Remember Me
Show More
Add this resume to contact form Yes No
Back to Search Result GO

Global Life Science Consultant and Expert Witness in the Pharmaceutical and IP Industries

Technical Consultant #2028


  • Commercial leadership in the global life sciences industries, with extensive experience guiding both large and small life-science companies.
  • Life science commercial strategy development.
  • Product development (commercial): Clinical study design, labeling development, and KOL networks.
  • Product launch in various disease states and platforms including diagnostics, vaccines and nutriceuticals.
  • Market access strategy development: expert recommendation, Key Opinion Leader (KOL) in support, pricing, policy, coverage and reimbursement.
  • Disease awareness strategy and program development.
  • Positioning of products or companies in competitive markets.
  • Overall pharmaceutical support in business strategy, tactical development, new product launches, profit and loss management, and sales and marketing.
  • Cross cultural team leader and collaborator with experience in Europe, North America, Latin America, the Middle East, and Asia.
  • Competitive Assessment and brand and company differentiation.

Expert Witness Experience

  • Grand Jury Testimony - Pharmaceutical in several cases: Medical education, marketing, and pricing practices for the U.S. District Court, Boston, MA.
  • Department of Justice Inquiry - Pharmaceutical pricing and contracting for the U.S. District Court, Boston, MA
  • Deposition - Pharmaceutical patent infringement and penalty phase infringement, Philadelphia, PA.
  • Legal Strategy Development - Pricing practices civil case, Collegeville, PA.


Undisclosed Company, Owner, 2011 - Present

  • Advised senior leaders on launch and commercialization strategy for biotechnology products.
  • Monitor, communicate and consult on vaccine industry trends.
  • Developed comprehensive global launch plan for 2nd generation TB vaccine.
  • Developed and presented (venture capital) business plan for new medical supply company.

Clients and Projects - Biotechnology Consulting

Undisclosed Company, Dietary Supplement and Launch

  • Develop commercial plan.
  • Obtain investor funding.
  • Secure partnership agreements.

Silagene, Inc., Hillsboro NJ

  • Support request for funding grant.
  • Provide commercial assessment.

Institutes for Pharmaceutical Discovery, Branford, CT

  • Developing and launching unique business opportunities for medical markets.
  • Secured funding and acquired rights to market a unique dietary supplement to medical specialties.
  • Developed business plan, branding etc. for the launch of a unique supplement.
  • Launched a uniquely positioned dietary supplement through urology specialists' medical practices.
  • Hired and managed a team of 5 employees to conduct the launch and marketing of the new product.

Emergent Biosolutions, Rockville, MD

  • Developed global business plan for a new tuberculosis vaccine.
  • Developed a global partnering and sales model for a new vaccine business unit.


Pfizer Pharmaceuticals, Vaccines, Collegeville, PA, Vice President, 2009 - 2010

  • Supported the launches of Prevenar 13 for both infant and adult indications
  • Co-led the team to refine the global vaccines business strategy for Pfizer and provided recommendations on internal and external assets in pursuit of portfolio strategy.
  • Evaluated and met with vaccine companies to discuss a variety of vaccine technology acquisitions.
  • Evaluated and provided commercial recommendations on new vaccine technologies.
  • Developed business governance structure for the global network of vaccines businesses.
  • Member of the Vaccines Leadership and Infectious Disease Area Leadership Teams.
  • Advised commercial groups on global vaccine policy issues.

Wyeth Pharmaceuticals, Vaccines, Collegeville, PA, 1991 - 2010

  • Serving the positions of Vice President and Global Business Manager of adult vaccines.
  • For a new commercial vaccine group built, launched the next blockbuster vaccine and first adult pneumococcal conjugate vaccine with expected growth of over $2 billion.
  • Created vision and strategy for building a marketing department to launch first of a kind adult vaccine, and recruited a new team of 14 marketing specialists.
  • Developed global launch strategy, branding, and positioning for a new pneumococcal vaccine.
  • Secured over $40 million in global funds and expanded the global team to 25 professionals.
  • Global profit and loss responsibility; U.S. P&L responsibility and direct management.
  • Designed and supported implementation of the U.S. adult vaccine sales force, (recruits and deploy).
  • Led the process to train and target adult vaccine sales force.
  • Led the process for supporting policy and positive recommendation (ACIP) for PCV13 in U.S. and to support similar recommendations within the EU, Latin America and Asia.
  • Built alliances with infectious disease organizations (NFID, ESCMID, ASM, FIDEC and IDSA).
  • Established strong relationships with GMs, marketing directors, meeting in various locations, Europe, Latin America and Asia.
  • Networked and strengthened relationships with, global government and NGO infectious disease organizations relating to adult vaccine policy, (e.g., CDC, WHO, ECDC).

Assistant Vice President, Vaccines New Business - Prevenar 13, 2006 - 2008

  • Responsible for developing and executing the global launch strategy and plan for Prevenar 13 pediatric and adult indications.
  • Developed global launch strategy for launching PCV13 in the competitive pediatric market and the new adult indication.
  • Communicated these strategies effectively to all affiliate General Managers and marketing teams.
  • As Chairman of the Global Launch Committee, partnered with General Managers of major European, Latin American and Asian affiliates to structure launch investment and approach.
  • Designed structure and recruited marketing personnel for both pediatric and adult global teams.
  • Co-developed lifecycle strategy for pneumococcal vaccine franchise.
  • Created a new marketing department to prepare for the launch of Wyeth's largest vaccine.
  • Provided input for clinical and regulatory strategy.

Assistant Vice President, Cardiovascular Business, Altace Marketing, 2005 - 2006

  • Appointed by and reported to Executive VP and GM of Pharma Business Unit.
  • Led U.S marketing group.
  • Differentiated Altace in highly genericized ACE Inhibitor market through unique indication.
  • U.S. profit and loss responsibility $105 million marketing and sales spend annually.
  • Increased profit by 25% ($20 million) through increased sales and eliminating unnecessary spending.
  • Optimized asset by restructuring licensing deal which retained annual revenue of over $225 million.
  • Boosted profit by eliminating unproductive promotional activity.
  • Directly negotiated divestiture of asset as well as terms of new partnership.
  • Commercial representative on cross functional licensing and acquisitions team for CV/GI and other non-core technology areas.
  • Managed co-marketing and sales alliance with King Pharmaceuticals.

Area Business Director, Sales Management, NE Business Unit, 2003 - 2004

  • Led and managed the regional sales force in two states (PA & WV). The team consisted of 10 sales directors, 10 specialty and 105 primary care sales representatives.
  • Position included sales goal attainment as well as leadership and human resource management responsibilities.
  • Improved area ranking from 15 to 5 (out of 23) areas in U.S.
  • Generated over $50 million growth in PA and WV off of a base of $400 million.
  • Restructured Psychiatry Specialty group to enhance performance in key product.
  • Introduced a new management advancement program based on sales results and management skills.
  • Subsequently promoted 18 representatives or managers in two years.
  • Selected as member of Senior Sales Council.

Group Product Director, Gastrointestinal Marketing, PPI, Protonix®, 2001 - 2003

  • Marketing: Reported to VP of GI/CV Marketing.
  • Developed highly successful launch strategies for the Hospital, Specialty and Primary Care markets.
  • U.S. profit and loss responsibility; over $200 million marketing and sales budget annually.
  • Fastest product in corporate history to reach $1 billion in annual sales (peak over $2 billion).
  • Product attained #1 status in hospital and MCO formularies for PPI class (audited).
  • Successfully managed a variety of supply chain issues and prevented lost sales.
  • Launched first intravenous proton pump inhibitor.
  • Directed launch of Protonix; categorized in the top 10-best pharmaceutical launches in the U.S.
  • Provided commercial recommendation for the Wyeth to acquire the license of pantoprazole.
  • Managed business alliance with Byk Gulden / Altana Pharmaceuticals (Germany).
  • Renegotiated product agreement with Byk to extend marketing reach and improve P&L.
  • Managed U.S. lifecycle strategy for pantoprazole based compounds.
  • Evaluated, proposed and pursued new business opportunities in GI area including proton pump inhibitors, prokinetics and combination therapies.
  • Transferred site of manufacture to save an additional $10 million in COGs.

Product Director, Gastrointestinal Marketing, PPI - Protonix, 1998 - 2001

  • Position established to brand, position, price, messaging, and launch new GI product.

Senior Product Manager, Musculoskeletal, Anti-Arthritics (NSAID), Lodine®, 1995 - 1998

  • Marketing and Business Development accountability.

International Product Manager, Diabetes, Alredase®, 1991 - 1995

  • Responsible for helping marketing director construct a business model and launch the first aldose reductase inhibitor for preventing diabetic complications.
  • Focused on markets in Europe, Asia and Latin America.

Honors & Publications


  • Executive Education Course Work
  • Harvard Business / Harvard Law Schools-Vantage Negotiating Skills
  • University of Pennsylvania, Wharton Business School - Value Creation; Global Positioning
  • Wyeth Global Executive Leadership Program


  • Spanish


  • President's Golden Circle (Top 2% of company)
  • President's Excellence and Recognition Awards (Protonix Team)
  • Project Team Achievement Award, (pantoprazole)
  • Brand Team Award - Bronze, Product Management Today, Protonix
  • Reader's Choice - Bronze, Product Management Today, "Gerdie" campaign
  • Toth Award - Best of Show, Public Relations Society (National) "Protonix"


  • B.S. Biology, Ursinus College, Collegeville, PA
Back to Search Result GO